EcoR1 Capital, LLC 13D and 13G filings for Kura Oncology, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 5:58 pm Purchase | 2023-12-31 | 13G | Kura Oncology, Inc. KURA | EcoR1 Capital, LLC | 7,598,797 9.990% | 960,426 (+14.47%) | Filing |
| 2023-02-10 1:48 pm Purchase | 2022-12-31 | 13G | Kura Oncology, Inc. KURA | EcoR1 Capital, LLC | 6,638,371 9.900% | 2,094,924 (+46.11%) | Filing |
| 2022-01-31 4:39 pm Purchase | 2022-01-21 | 13G | Kura Oncology, Inc. KURA | EcoR1 Capital, LLC | 4,543,447 6.800% | 2,770,410 (+156.25%) | Filing |
| 2021-02-16 12:00 pm Sale | 2020-12-31 | 13G | Kura Oncology, Inc. KURA | EcoR1 Capital, LLC | 1,773,037 2.700% | -2,468,916 (-58.20%) | Filing |
| 2020-02-14 2:31 pm Sale | 2019-12-31 | 13G | Kura Oncology, Inc. KURA | EcoR1 Capital, LLC | 4,241,953 9.400% | -1,034,800 (-19.61%) | Filing |